Search companies

Live

Tuesday, 17 November 2026 · 583 Summaries Today

S&P/ASX 200 · 8,883.20 (-1.79%)

Optiscan Lodges Two U.S. FDA Applications, Advancing Devices Into Review

OIL: $0.155 +3.33% · MC: $162M

Optiscan says it lodged U.S. FDA applications for its InForm digital pathology and InVue precision surgery devices shortly after quarter-end, moving both into formal review; U.S. market entry remains subject to clearance. The company also signed two Mayo Clinic research agreements and launched its InSpecta veterinary device in the U.S. during the quarter.

Source announcements: 2026-10-30 08:57 to 2026-10-30 08:57 Sydney time
Story updated 2026-10-30 12:01 Sydney time
SourcesQuarterly Activities/Appendix 4C Cash Flow Report
Comments